

THE LEEDS TEACHING HOSPITALS NHS TRUST

Request for Approval of Contract

Contract Title: Onco-type DX Breast recurrence Score test.

Period: 1st July 2025 to 30th June 2026

Proposed Supplier(s) Exact Sciences UK

Total Contract Value ex VAT £191,700.00

Recurrent revenue within budget allocation Yes

Capital costs allocated NA

If over threshold for:-

Capital Programme Group

Finance & Performance Committee £1m or above

Trust Board £3.5m or above

Approval obtained on

Approval obtained on

Approval obtained on

Additional comments to support request for contract approval:

This request relates to an extension of the current contract, which expired on **30 June 2025**,

This request relates to an extension of the current contract, which expired on 30 June 2025, under the NHSSC Framework 2023/S 000-028831.

The Trust has an ongoing requirement to procure the Oncotype DX Test, a diagnostic assay developed for patients with early-stage HR+, HER2- breast cancer. The test identifies those patients who are likely to derive clinical benefit from chemotherapy.


The Oncotype DX test remains the only multigene assay that is clinically validated to predict chemotherapy benefit and is uniquely available on the global market.

The processing of this extension has been delayed due to staff sickness; however, it remains essential to proceed to ensure continuity of service and avoid any detriment to patient care. Extending the current contract will maintain timely access to this critical diagnostic test.

Signed (Responsible Officer).....  Name Lorraine Byron

Position: Contracting Manager

Date 20/10/2025

Signed 

(Director, Commercial and Procurement)

Date 20/10/2025